primary%20open-angle%20glaucoma
PRIMARY OPEN-ANGLE GLAUCOMA
Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.

Follow Up

  • Primary open-angle glaucoma (POAG) patients require lifetime therapy & monitoring of intraocular pressure (IOP), visual fields & optic disc
  • Follow-up visits are usually at least 2x a year but frequency may depend on extent of damage, presence of progression, stability of IOP control & patient compliance
  • Measure visual acuity, IOP & perform slit-lamp biomicroscopy
  • Gonioscopy may be performed every 1-5 years but is warranted in cases of unexplained IOP changes or if w/ suspicion of anterior chamber abnormalities
  • Indications for therapy adjustments include:
    • Failure to achieve target IOP
    • Progressive optic nerve damage despite achieving target IOP
    • Medication intolerance or patient has developed contraindications to the medications
    • Poor patient compliance 
  • Poor control of IOP warrants adjustment of therapy for which a patient may be seen every 2-4 weeks
  • Consider increasing target IOP if the patient has been stable & either requires or desires less medication
  • Consider decreasing target IOP in the presence of visual field deterioration or progressive optic disc damage

Expert Referral

  • Consultation or referral to an ophthalmologist w/ special training or experience in glaucoma management
  • Patients w/ significant or progressive loss of vision may be referred for vision rehabilitation & social services
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 5 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.